China to approve imports of hemophilia treatment

09/20/2007 | China Daily (Beijing)

China plans to approve imports of a Bayer Healthcare recombinant-clotting factor to ease the country's current medication shortage for hemophilia patients. Officials stressed they are not easing an existing ban on imported blood and plasma-derived products because the treatment is not made from human plasma.

View Full Article in:

China Daily (Beijing)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC